The DOI matches its Crossref record; 304 of the 332 references it cites were found in a registry or an index, and 21 are not checked yet; 105 of the 438 sources its claims cite were checked for support.
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Open accessAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective in the management of obesity; however, their efficacy and tolerability may be further optimized through complementary nutritional strategies. Such interventions may address key challenges associated with GLP-1RA therapy, including gastrointestinal adverse effects, lean mass loss, and reduced long-term adherence leading to weight regain. Evidence from preclinical and clinical studies indicates that omega-3 polyunsaturated fatty acids may enhance the metabolic benefits of GLP-1RAs and attenuate lean mass loss, primarily via anti-inflammatory pathways and modulation of protein synthesis. Synergistic effects have also been reported with other bioactive compounds—such as flavonoids and anthocyanins, which improve metabolic outcomes; probiotics and prebiotics, which may alleviate gastrointestinal intolerance; and high-quality protein sources, which support body composition preservation. Collectively, these findings suggest that nutritional adjuncts may complement GLP-1RA therapies through convergent physiological mechanisms, including the regulation of inflammation, gut microbiome composition, and cellular metabolism. While current data highlight the promise of integrated pharmaco-nutritional strategies as adjuncts to GLP-1-based obesity therapy, further randomized controlled trials are needed to establish the most effective interventions and protocols.
Verified 2026-10-05 · 21 references not checked yet
Overview
CoChat Summary
TL;DR
This narrative review argues that nutritional adjuncts—fiber/prebiotics, probiotics, protein sources, specific nutrients, and botanical actives—may complement GLP-1 receptor agonist (GLP-1RA) therapy in obesity by improving GI tolerability, preserving lean mass, and amplifying metabolic benefits. However, direct clinical evidence combining these interventions with GLP-1RAs remains scarce, and most proposed synergies are based on indirect, preclinical, or expert-consensus evidence.
Key findings
- GLP-1RAs achieve placebo-adjusted weight loss of 8–21% after one year, but long-term effectiveness is limited by GI adverse events affecting up to 70–85% of patients, nutritional deficiencies, lean mass loss, and weight regain—with up to two-thirds of lost weight returning within one year after discontinuation.
- Nutritional adjuncts with the strongest practice-reasonable support include adequate protein intake, ginger, dietary fiber, and probiotics for preserving lean mass and improving GI tolerability; expert consensus recommends fiber for constipation and probiotics for persistent diarrhea during GLP-1RA treatment.
- Specific evidence cited includes a pilot study of 27 obese patients where a multispecies probiotic plus low-dose liraglutide produced comparable weight loss to higher-dose liraglutide alone, with 59.3% reporting only mild transient GI symptoms and none discontinuing, versus an 80.3% adverse-event incidence in a comparable high-dose liraglutide trial.
- Other reported findings include L. gasseri BNR17 producing a ~22 cm² decrease in visceral adiposity versus placebo; oral glutamine (15 g/day) achieving ≥50-point IBS severity score reduction in 79.6% vs 5.8% with placebo; and omega-3/krill oil trials showing muscle function or lean-mass benefits, though omega-3 evidence is described as mixed.
Methods
- Narrative review with a targeted, non-systematic search in PubMed, Scopus, Google Scholar, and Cochrane up to September 2025, plus manual reference searching.
- Search terms included “GLP-1,” “GLP-1 receptor agonists,” drug names (semaglutide, liraglutide, tirzepatide), intervention descriptors (“nutrition,” “dietary interventions,” “nutraceuticals”), and specific actives (“probiotics,” “fibers,” “botanical extracts”).
- The review prioritized English-language clinical and preclinical studies reporting metabolic and/or GI tolerability outcomes relevant to GLP-1RA therapy, synthesizing preclinical, indirect clinical, and direct clinical findings when available.
Limitations
- The paper states that direct clinical evidence combining nutritional interventions with GLP-1RAs remains limited, that many compounds have not been studied in combination with GLP-1RAs, and that further randomized controlled trials are needed to establish effective interventions and protocols.
- The paper notes that nutritional supplements differ from pharmacological agents in regulatory classification and are not subject to the same pre-market clinical validation, and advises caution in vulnerable populations such as pregnant/lactating women, older adults, critically ill patients, and those with hepatic or renal impairment.
- Evident from the text: the search was non-systematic, with no described protocol, risk-of-bias assessment, or formal evidence grading; many proposed benefits rely on preclinical data, studies in non-GLP-1RA populations, or expert consensus, so several adjunctive roles remain hypothetical.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
24 Valid · 41 Not valid · 244 Not checked · 59 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A meta-analysis of 16 randomized controlled trials with 1251 adults with chronic constipation showed that fiber, particularly psyllium at doses >10 g/day for ≥4 weeks, significantly improved stool frequency and consistency [132]”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.1. Dietary Fibers and Prebiotics
What the sources say
- Disputedcites [132] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainstates a causen = 1,251- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A meta-analysis of 37 randomized controlled trials confirmed that higher protein intake reduced body weight by ~1.6 kg, with prediabetic subjects benefiting the most [163].”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.3. Protein Sources
What the sources say
- Disputedcites [163] sourceExperimental — accuracy not yet measured
The Results (Characteristics of included studies; page unavailable) state that this meta-analysis included 22 studies, not 37. The paper reports glycemic and lipid outcomes, but does not report the claimed ~1.6 kg reduction in body weight or a greatest benefit among prediabetic subjects. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In older adults, >2 g/day was associated with modest gains in muscle mass (0.67 kg) and improvements in walking speed, particularly after interventions > 6 months (1.78 m/s; 95% CI: 1.38-2.17)[190].”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.4.4. Omega-3 Polyunsaturated Fatty Acids
What the sources say
- Disputedcites [190] sourceExperimental — accuracy not yet measured
The Results (Eligible studies and baseline characteristics; page unavailable) state that treatment lasted 3–24 weeks, contrary to the claim of an effect particularly after interventions longer than six months. The Methods (Statistical analysis; page unavailable) identify weight, BMI, waist circumference, lipids, and glucose as outcomes; the paper does not report the claimed walking-speed estimate or muscle-mass gain in older adults. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Another randomized controlled trial with 41 overweight/obese adults undergoing an alternate-day fasting regimen showed that KO (4 g/day, SuperbaBoost™, Aker BioMarine ASA, Lysaker, Norway) for 8 weeks attenuated declines in fat-free mass (-0.2 ± 0.9 kg) and handgrip strength (-0.2 ± 0.5 kg) observed in the placebo group [308].”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.4.4. Omega-3 Polyunsaturated Fatty Acids
What the sources say
- Disputedcites [308] sourceExperimental — accuracy not yet measured
The Methods (Study population and Intervention; page not provided) describe a 28-day krill-oil study in healthy young adults, with 17 included in the analysis; obesity was an exclusion criterion. Participants were advised to maintain their body weight, not undergo alternate-day fasting. The cited paper therefore describes a different study and does not report the claimed placebo comparison or fat-free-mass and handgrip outcomes. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In metabolic syndrome, pine bark extract (150 mg/day, for 6 months) improved key risk factors: it lowered fasting glucose (~123 to ~105 mg/dL), reduced waist circumference (-7.9 cm in men and -7.3 cm in women), increased adiponectin, and reduced blood pressure and oxidative stress markers [213].”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.5.4. French Maritime Pine (Pinus pinaster) Bark Extract
What the sources say
- Disputedcites [213] sourceExperimental — accuracy not yet measured
Table 2 and §3.2 report fasting-glucose results for Guava Leaf Tea, not pine bark extract: 136 to 131 mg/dL after 12 weeks in pre-diabetic and mildly diabetic subjects. The cited paper does not report the claimed 150 mg/day, six-month pine-bark regimen or the change from approximately 123 to 105 mg/dL. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
210 more claims · 42 with their cited sources checked
Create a free account to see all 368 claims and to verify the 333 references still open.
- It may state two separate claims as one. 138
- Probably not a substantial claim. 20
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, distributing protein intake evenly across meals has been found to be particularly effective, as it maximizes muscle protein synthesis throughout the day [72].”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > 3.4.3. Zinc
“Evidence from animal models shows that zinc supplementation reduces weight gain, abdominal fat accumulation, hyperinsulinemia, and leptin levels, while improving insulin resistance in obese mice fed a high-fat, high-fructose diet [183].”
§ Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review > References
“Thoen, R.U.; Barther, N.N.; Schemitt, E.; Bona, S.; Fernandes, S.; Coral, G.; Marroni, N.P.; Tovo, C.; Guedes, R.P.; Porawski, M. Zinc supplementation reduces diet-induced obesity and improves insulin sensitivity in rats.”
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Brauer, M., Roth, G. A., Aravkin, A. Y., Zheng, P., Abate, K. H., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasi, M. A., Abbasian, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00933-4 · Cited by 2,884
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 3×
“…insulin secretion from pancreatic β -cells [32], stimulates somatostatin secretion from δ -cells, which suppresses glucagon secretion from α -cells [31], and exerts cytoprotective effects on β -cells by inhibiting apoptosis, inducing proliferation, and supporting insulin biosynthesis [31,36].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Bioactive Compounds and Bioactivities of Ginger (Zingiber officinale Roscoe)
Mao, Q.-Q., Xu, X.-Y., Cao, S.-Y., Gan, R.-Y., Corke, H., Beta, T., & Li, H.-B. (2019) · Foods · doi:10.3390/foods8060185 · Cited by 1,418
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“Although GLP-1RAs induce substantial weight loss and metabolic improvements, their long-term effectiveness is limited by challenges such as weight regain after discontinuation, with up to two-thirds of the lost weight returning within one year [56–58].”
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 1×
“Complementary nutritional interventions are therefore crucial for the long-term success of GLP-1RA therapy, with studies showing that nutritional counselling improves results and adherence through individualized guidance and management of adverse effects [27–30].”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · cited 3×
“Structural modifications of the GLP-1 molecule led to the development of GLP-1RAs with prolonged half-life, enabling sustained glycemic control and weight reduction [33,38,40].”
Dietary fibre in gastrointestinal health and disease
Gill, S. K., Rossi, M., Bajka, B., & Whelan, K. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00375-4 · Cited by 979
Research works printed but not linked: 13
- Choi, 2019, Oral Collagen Supplementation: A Systematic Review of Dermatological Applications, J. Drugs Dermatol., 18, 9
- Modi, M., and Modi, K. (2025, November 19). Ginger Root, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK565886/.
- Guarneiri, 2025, Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes, J. Am. Nutr. Assoc., 44, 306
- Deguchi, 2000, Effectiveness of consecutive ingestion and excess intake of guava leaves tea in human volunteers, J. Jpn. Council. Adv. Food Ingred. Res., 3, 19
- Giacosa, 2015, Can nausea and vomiting be treated with ginger extract?, Eur. Rev. Med. Pharmacol. Sci., 19, 1291
- Pongrojpaw, 2007, A randomized comparison of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy, J. Med. Assoc. Thail., 90, 1703
- Dayib, 2020, Dietary fibers reduce obesity-related disorders: Mechanisms of action, Curr. Opin. Clin. Nutr. Metab. Care, 23, 445
- Barakat, 2020, Bovine Colostrum in the Treatment of Acute Diarrhea in Children: A Double-Blinded Randomized Controlled Trial, J. Trop. Pediatr., 66, 46
- Kannappan, 2006, Cinnamon bark extract improves glucose metabolism and lipid profile in the fructose-fed rat, Singap. Med. J., 47, 858
- Javed, 2012, Lipid lowering effect of Cinnamomum zeylanicum in hyperlipidaemic albino rabbits, Pak. J. Pharm. Sci., 25, 141
- Ahmad, 2025, Ameliorating implications of Psidium guajava L. (guava) leaf against metabolic syndromes—A review, J. Agric. Food Res., 21, 101867
- Amin, A.N., Intang, I.N., and Alfira, N. (2024). Effect of guajava (Psidium) leaves decoction on changes in blood glucose levels of people with diabetes mellitus. Proc. Optim., 1.
- Salaramoli, 2022, The effects of ginger and its constituents in the prevention of metabolic syndrome: A review, Iran. J. Basic Med. Sci., 25, 664
Cited by
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026) · Nutrients · doi:10.3390/nu18040632 · Cited by 11
“More-over, distributing protein intake evenly across meals has been found to be particularly effective, as it maximizes muscle protein synthesis throughout the day [72].”
Tjandrawinata, R. R., Rosari, B. P., Syahputra, R. A., Surya, R., & Nurkolis, F. (2026) · Nutrients · doi:10.3390/nu18030547 · Cited by 9
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“…to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
Benito‐Vázquez, I., Rosell, M. D. L. Á., Lates-Profir, N., Díez‐Municio, M., Moreno, F. J., Frontela‐Saseta, C., & López-Nicolás, R. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107414 · Cited by 1
Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care
Cozma-Petruț, A. P., Gherghel, M., Banc, R., Tișa, I. B., Stanciu, O., Coldea, T. E., Mudura, E., Miere, D., & Filip, L. A. (2026) · Nutrients · doi:10.3390/nu18162691 · Cited by 1
Metadata
- Authors
- Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J.
- Affiliations
- Kilyos Assessoria, Cursos e Palestras, São Paulo 01311-100, Brazil
- Corresponding author
- Name, José João
- Venue
- Obesities
- Publisher
- MDPI AG
- Published
- 2025-12-02
- Volume
- 5
- Issue
- 4
- Pages
- 88
- ISSN
- 2673-4168 (ISSN-L)
- OpenAlex
- W4417124127
- Cited by
- 8
- References
- 324
- Citations by year
- 2026: 8
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Obesities (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, omega-3 polyunsaturated fatty acids, lean mass loss, gastrointestinal adverse effects, weight regain, probiotics and prebiotics, flavonoids, anthocyanins, high-quality protein, gut microbiota, inflammation, body composition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review. https://app.cochat.ai/papers/10.3390/obesities5040088
- The paper
- Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025). Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review. Obesities. https://doi.org/10.3390/obesities5040088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.